The company is launching a call for innovation for early-stage start-ups focused on developing digital health services and solutions to tackle some of the present and future dermatological challenges The call was launched at the first Barcelona Health Hub Summit,…
BACK Real-world or real evidence? Real-world or real evidence?
There was a time when the distinction between data from clinical trials and data from any other source was clear. Clinical trials created clinical evidence to determine regulatory decisions and guide clinical practice; whereas all other data was of second…
Novartis says mid-stage pipeline is setting up strong growth spurt
Novartis kicked off its R&D update in London this morning by pledging to bring at least 10 drugs into pivotal trials in 2020 and 2021 from a mid-stage pipeline packed with 60 projects. All told, the Swiss group says it…
Acadia’s Nuplazid Hits the Mark in Late-Stage Dementia-Related Psychosis Trial
Shares of ACADIA Pharmaceuticals are soaring in premarket trading after the company announced full positive results from its Phase III HARMONY study evaluating Nuplazid (pimavanserin) for the treatment of dementia-related psychosis. The stock is up more than 20% to $53.26.…
Mylan and Biocon launch Herceptin biosimilar in US
Mylan and Biocon have launched their Herceptin biosimilar Ogivri in the US, the second challenger to Roche’s breast and stomach cancer blockbuster. The companies said that they launched Ogivri at a “competitive advantage” compared with Herceptin (trastuzumab) but gave no…
Astellas buys gene therapy company for $3bn
Astellas has announced it will be acquiring gene therapy specialists Audentes Therapeutics for a total equity value of approximately $3 billion, adding a new focus area to its drug discovery efforts. The deal gives Astellas access to Audentes’ AT132, in…
Neurocrine and Xenon agree $1.75bn epilepsy R&D tie-up
Two biotechs, Neurocrine Biosciences and Xenon, have announced a licence and collaboration agreement to develop first-in-class treatments for epilepsy in a deal worth up to $1.75 billion. Epilepsy is one area of neurology where pharma is having limited success –…
US eyes faster launch for biosimilars in North American trade pact; reports
Biosimilars could be brought to market much quicker in North America if a Trump administration proposal makes it into a new US-Canada-Mexico (USMCA) trade pact, according to press reports. Citing people familiar with the matter, the Wall Street Journal says…
Irish medtech sees continuing import boom from UK
Ireland’s medtech industry is importing more raw materials to keep pace with demand for its products, according to data published by the foreign exchange specialist Fexco International Payments. The analysis, of more than 7,500 transactions made through Fexco International Payments,…
Medical devices are bigger culprit in antibiotic-resistant infections than surgical procedures: CDC analysis
Dive Brief: Healthcare-associated infections (HAIs) that are antibiotic-resistant resulted more frequently from use of temporary medical devices than from surgical procedures, according to an analysis of patient data from 5,626 sites reported to the Centers for Disease Control and Prevention’s…
